Evidence map›Paper›PMID 36900721›Full record

ReviewHealthcare (Basel, Switzerland)2023

Chronic Insomnia Disorder across Europe: Expert Opinion on Challenges and Opportunities to Improve Care.

Jason Ellis, Luigi Ferini-Strambi, Diego García-Borreguero, Anna Heidbreder, David O'Regan, Liborio Parrino, Hugh Selsick, Thomas Penzel

Full text readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Is there a better way to wean chronic benzodiazepine receptor agonists use by substituting a DORA (and starting CBT-I)?Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jason EllisDepartment of Psychology, Northumbria University, Newcastle NE1 8ST, UK.ORCID 0000-0002-8496-520X
Luigi Ferini-StrambiDepartment of General Psychology, Università Vita-Salute San Raffaele, 20132 Milan, Italy.
Diego García-BorregueroSleep Research Institute, 28036 Madrid, Spain.
Anna HeidbrederDepartment of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria.
David O'ReganFaculty of Life Sciences and Medicine, King's College, London WC2R 2LS, UK.ORCID 0000-0002-3809-022X
Liborio ParrinoDepartment of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy.
Hugh SelsickInsomnia and Behavioural Sleep Medicine Clinic, University College London Hospitals, London NW1 2PG, UK.
Thomas PenzelInterdisciplinary Centre of Sleep Medicine, Medicine Centre, Charité Universitätsmedizin, 10117 Berlin, Germany.ORCID 0000-0002-4304-0112

Funding

Idorsia (Switzerland) not applicable
6 · The paper itself

Abstract

One in ten adults in Europe have chronic insomnia, which is characterised by frequent and persistent difficulties initiating and/or maintaining sleep and daily functioning impairments. Regional differences in practices and access to healthcare services lead to variable clinical care across Europe. Typically, a patient with chronic insomnia (a) will usually present to a primary care physician; (b) will not be offered cognitive behavioural therapy for insomnia-the recommended first-line treatment; (c) will instead receive sleep hygiene recommendations and eventually pharmacotherapy to manage their long-term condition; and (d) will use medications such as GABA receptor agonists for longer than the approved duration. Available evidence suggests that patients in Europe have multiple unmet needs, and actions for clearer diagnosis of chronic insomnia and effective management of this condition are long overdue. In this article, we provide an update on the clinical management of chronic insomnia in Europe. Old and new treatments are summarised with information on indications, contraindications, precautions, warnings, and side effects. Challenges of treating chronic insomnia in European healthcare systems, considering patients' perspectives and preferences are presented and discussed. Finally, suggestions are provided-with healthcare providers and healthcare policy makers in mind-for strategies to achieve the optimal clinical management.

Indexed as

chronic insomniacognitive behavioural therapyEuropegeneral practitionershealthcare policyhealthcare providershypnoticspharmacotherapysleep

Identifiers

PMID36900721
PMCPMC10001099

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read62
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.